Endocrine and metabolic emergencies: hypercalcaemia

被引：19

作者：

Carroll, Richard ^{[1
]}

Matfin, Glenn ^{[2
,3
]}

机构：

[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England

[2] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA USA

[3] NYU, Sch Med, Div Endocrinol, New York, NY USA

来源：

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM | 2010年 / 1卷 / 05期

关键词：

hypercalcaemia; hypercalcaemic crisis; hyperparathyroidism; malignancy-associated hypercalcaemia;

D O I：

10.1177/2042018810390260

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypercalcaemia is commonly seen in the context of parathyroid dysfunction and malignancy and, when severe, can precipitate life-threatening sequelae. The differential of hypercalcaemia is broad and can be categorized based on parathyroid hormone (PTH) levels. The acute management of severe hypercalcaemia is discussed along with a brief review of therapeutic advances in the field.

引用

页码：225 / 234

页数：10

共 30 条

[21] A RANDOMIZED DOUBLE-BLIND COMPARISON OF INTRAVENOUS PAMIDRONATE AND CLODRONATE IN THE HYPERCALCEMIA OF MALIGNANCY [J].

PUROHIT, OP ;

RADSTONE, CR ;

ANTHONY, C ;

KANIS, JA ;

COLEMAN, RE .

BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1289-1293

[22] Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia [J].

Ralston, SH ;

Thiebaud, D ;

Herrmann, Z ;

Steinhauer, EU ;

Thurlimann, B ;

Walls, J ;

Lichinitser, MR ;

Rizzoli, R ;

Hagberg, H ;

Huss, HJ ;

TubianaHulin, M ;

Body, JJ .

BRITISH JOURNAL OF CANCER, 1997, 75 (02) :295-300

[23]

Reszka A. A., 2010, BISPHOSPHONATE MECH

[24]

Selby P., 2002, CLIN REV BONE MINERA, V1, P3

[25]

Shoback D.G.G.a.D., 2007, GREENSPANS BASIC CLI

[26] Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma [J].

Silverberg, S. J. ;

Rubin, M. R. ;

Faiman, C. ;

Peacock, M. ;

Shoback, D. M. ;

Smallridge, R. C. ;

Schwanauer, L. E. ;

Olson, K. A. ;

Klassen, P. ;

Bilezikian, J. P. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (10) :3803-3808

[27] Hypercalcemia associated with cancer [J].

Stewart, AF .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (04) :373-379

[28] Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system [J].

Tanaka, S ;

Nakamura, K ;

Takahasi, N ;

Suda, T .

IMMUNOLOGICAL REVIEWS, 2005, 208 :30-49

[29] Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min:: a randomized, open-label study [J].

von Moos, R. ;

Caspar, C. B. ;

Thuerlimann, B. ;

Angst, R. ;

Inauen, R. ;

Greil, R. ;

Bergstrom, B. ;

Schmieding, K. ;

Pecherstorfer, M. .

ANNALS OF ONCOLOGY, 2008, 19 (07) :1266-1270

[30] Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice [J].

Yamada, Tadaaki ;

Muguruma, Hiroaki ;

Yano, Seiji ;

Ikuta, Kenji ;

Ogino, Hirokazu ;

Kakiuchi, Soji ;

Hanibuchi, Masaki ;

Uehara, Hisanori ;

Nishioka, Yasuhiko ;

Sone, Saburo .

MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) :119-126

← 1 2 3 →